Norgine Germany

Norgine Germany company information, Employees & Contact Information

Explore related pages

Related company profiles:

Norgine ist ein führendes europäisches Spezialpharmaunternehmen, das seit mehr als einem Jahrhundert den Patienten Medikamente zur Verfügung stellt. Unser Engagement, das Leben der Menschen zu verändern, ist der Antrieb für alles, was wir tun. Unsere europäische Erfahrung, unsere voll integrierte Infrastruktur und unser außergewöhnlicher partnerschaftlicher Ansatz ermöglichen es uns, schnell kreative Lösungen anzuwenden, um Patienten lebensverändernde Medikamente zur Verfügung zu stellen, zu denen sie sonst vielleicht keinen Zugang hätten. Norgine ist stolz darauf, Jahr für Jahr Millionen Patientinnen und Patienten auf der ganzen Welt helfen zu können und gemeinsam mit ihnen neue Wege zu gehen - so auch zukünftig in der pädiatrischen Onkologie. Norgine ist in 12 europäischen Ländern sowie in Australien und Neuseeland direkt vertreten. Darüber hinaus verfügen wir über ein starkes globales Netzwerk von Partnerschaften in Märkten, die nicht zu Norgine gehören. Wir sind ein flexibles und voll integriertes pharmazeutisches Unternehmen mit Produktionsstätten (Hengoed, Wales und Dreux, Frankreich), Drittlieferantennetzwerken und bedeutenden Produktentwicklungskapazitäten, die unsere Vertriebs- und Marketinginfrastruktur ergänzen. Dadurch sind wir in der Lage, spezialisierte und innovative Produkte zu erwerben, zu entwickeln und zu vermarkten, die das Leben von Patientinnen und Patienten auf der ganzen Welt wirklich verbessern. Impressum Herausgeber Norgine GmbH Im Westpark 14 35435 Wettenberg Tel: +49 (0) 641 98497 – 0 Fax: +49 (0) 641 33055908 E-Mail: info@norgine.de Handelsregisternummer HRB 9522 Amtsgericht Gießen Zuständige Aufsichtsbehörde: Regierungspräsidium Darmstadt Umsatzsteuernummer DE112589731 Geschäftsführer: Andreas Wöller, Simon Jose Datenschutzerklärung für unsere Social-Media-Seiten: https://www.norgine.de/datenschutzerklaerung-fuer-unsere-social-media-seiten/

Company Details

Employees
31
Founded
-
Address
Im Westpark 14, Wettenberg,hessen 35435,germany
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
norgine.de
Keywords
Dr. Ralf Eckert.
HQ
Wettenberg, Hessen
Looking for a particular Norgine Germany employee's phone or email?

Norgine Germany Questions

News

Norgine completes acquisition of Theravia - PR Newswire

Norgine completes acquisition of Theravia PR Newswire

Latham Advises Norgine on Acquisition of Theravia - Latham & Watkins LLP

Latham Advises Norgine on Acquisition of Theravia Latham & Watkins LLP

Epidemiology and treatment of patients with iron deficiency and iron deficiency anemia: a study on longitudinal German health claims data - BMC Public Health

Epidemiology and treatment of patients with iron deficiency and iron deficiency anemia: a study on longitudinal German health claims data BMC Public Health

Norgine strengthens rare disease portfolio with acquisition of Theravia - PR Newswire

Norgine strengthens rare disease portfolio with acquisition of Theravia PR Newswire

France: Mérieux Equity Partners sells stake in Theravia to Norgine - Investors in Healthcare

France: Mérieux Equity Partners sells stake in Theravia to Norgine Investors in Healthcare

Norgine secures Pedmarqsi licence from Fennec in deal worth up to $272m - Pharmaceutical Technology

Norgine secures Pedmarqsi licence from Fennec in deal worth up to $272m Pharmaceutical Technology

Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1] - PR Newswire

Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1] PR Newswire

X4 Pharmaceuticals and Norgine Enter into Exclusive - GlobeNewswire

X4 Pharmaceuticals and Norgine Enter into Exclusive GlobeNewswire

Norgine snaps up Theravia to bolster rare disease portfolio - FirstWord Pharma

Norgine snaps up Theravia to bolster rare disease portfolio FirstWord Pharma

Norgine boosts rare disease portfolio with buy of Theravia - The Pharma Letter

Norgine boosts rare disease portfolio with buy of Theravia The Pharma Letter

Norgine agrees to acquire pharma laboratory Theravia - Pharmaceutical Business review -

Norgine agrees to acquire pharma laboratory Theravia Pharmaceutical Business review -

HAS Rejects Early Access for Norgine’s Pedmarqsi in Pediatric Solid Tumors - NAVLIN DAILY

HAS Rejects Early Access for Norgine’s Pedmarqsi in Pediatric Solid Tumors NAVLIN DAILY

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma - PR Newswire

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma PR Newswire

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe. - PR Newswire

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe. PR Newswire

Norgine Announces Appointment of New CEO Janneke van der Kamp - PR Newswire

Norgine Announces Appointment of New CEO Janneke van der Kamp PR Newswire

Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer - PR Newswire

Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer PR Newswire

Norgine welcomes PBS listing in Australia of IFINWIL® (eflornithine) for patients with high-risk neuroblastoma (HRNB) - PR Newswire

Norgine welcomes PBS listing in Australia of IFINWIL® (eflornithine) for patients with high-risk neuroblastoma (HRNB) PR Newswire

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand - PR Newswire

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand PR Newswire

Swissmedic approves IFINWIL® (eflornithine) for children diagnosed with high-risk neuroblastoma (HRNB) - PR Newswire

Swissmedic approves IFINWIL® (eflornithine) for children diagnosed with high-risk neuroblastoma (HRNB) PR Newswire

Norgine B.V. Enters Into Exclusive Licence and Distribution Agreements for the Commercialisation of PLENVU® in a Number of Countries in Latin America, Southern Africa, Central and Eastern Europe - PR Newswire

Norgine B.V. Enters Into Exclusive Licence and Distribution Agreements for the Commercialisation of PLENVU® in a Number of Countries in Latin America, Southern Africa, Central and Eastern Europe PR Newswire

Norgine Announces Closing of Investment from Goldman Sachs Asset Management - PR Newswire

Norgine Announces Closing of Investment from Goldman Sachs Asset Management PR Newswire

Norgine on a growth charge again with Theravia takeover deal - pharmaphorum

Norgine on a growth charge again with Theravia takeover deal pharmaphorum

NICE recommends Norgine’s Pedmarqsi - The Pharma Letter

NICE recommends Norgine’s Pedmarqsi The Pharma Letter

Mérieux Equity Partners to sell Theravia to Norgine - pehub.com

Mérieux Equity Partners to sell Theravia to Norgine pehub.com

Pharmaceutical Company Norgine Shifts Stubborn Stool with Movicol Launch - Little Black Book | LBBOnline

Pharmaceutical Company Norgine Shifts Stubborn Stool with Movicol Launch Little Black Book | LBBOnline

Norgine Announces Investment from Goldman Sachs Asset Management - Notimérica

Norgine Announces Investment from Goldman Sachs Asset Management Notimérica

AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive - GlobeNewswire

AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive GlobeNewswire

A Comparative Clinical Study of a Novel Pre-colonoscopy Bowel Capsule Preparation Against Two Commercially Available Liquid Preparations - Frontiers

A Comparative Clinical Study of a Novel Pre-colonoscopy Bowel Capsule Preparation Against Two Commercially Available Liquid Preparations Frontiers

Norgine acquires Danish firm Azanta - The Pharma Letter

Norgine acquires Danish firm Azanta The Pharma Letter

Norgine B.V. announces Senior Management changes: Christopher Bath appointed Chief Executive Officer - Peter Stein to as - Notimérica

Norgine B.V. announces Senior Management changes: Christopher Bath appointed Chief Executive Officer - Peter Stein to as Notimérica

Norgine pension scheme agrees £28m buy-in with Canada Life - Pensions Age Magazine

Norgine pension scheme agrees £28m buy-in with Canada Life Pensions Age Magazine

Goldman Sachs’ PE arm to acquire majority stake in Amsterdam-based Norgine, reportedly for €1.8B - Silicon Canals

Goldman Sachs’ PE arm to acquire majority stake in Amsterdam-based Norgine, reportedly for €1.8B Silicon Canals

Norgine buys rights to sell Shield’s iron deficiency therapy - PharmaTimes

Norgine buys rights to sell Shield’s iron deficiency therapy PharmaTimes

Norgine goes to unitranche: trendsetter or outlier? - GlobalCapital

Norgine goes to unitranche: trendsetter or outlier? GlobalCapital

NORGINE B.V. ANNOUNCES NEW EUROPEAN HEALTHCARE SUBSIDIARY - MultiVu

NORGINE B.V. ANNOUNCES NEW EUROPEAN HEALTHCARE SUBSIDIARY MultiVu

Norgine scheme completes £28m buy-in with Canada Life - Professional Pensions

Norgine scheme completes £28m buy-in with Canada Life Professional Pensions

Norgine Buys Merus Labs for $342M - Contract Pharma

Norgine Buys Merus Labs for $342M Contract Pharma

Norgine opens new £4.5 million warehouse - Pharmafile

Norgine opens new £4.5 million warehouse Pharmafile

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant